LJUBLJANA (Slovenia), January 30 (SeeNews) – Slovenian pharmaceuticals producer Krka [LJE:KRKG] recorded a consolidated net profit of 242.1 million euro ($266.5 million) in 2019, up 39% on the year, the company said on Thursday, citing preliminary estimates of unaudited data.
Consolidated revenue increased to 1.49 billion euro from 1.33 billion euro in 2018, Krka said in a bourse filing.
The 2019 operating profit of the Krka group amounted to 274.0 million euro, up 18% year-on-year, while profit before tax totalled 283.7 million euro, up 40%.
The Krka group allocated 113 million euro to investments last year, of which 92 million euro to the controlling company.
“Our investments were made to increase and upgrade our manufacturing and development capacities, ensure quality assurance, and construct Krka production-and-distribution centres across the globe,” noted.
“Publication of the 2019 unaudited financial statements of the Krka group and Krka is scheduled for Thursday, 19 March 2020,” the company noted.
According to the 2020 plan, Krka group sales are projected at 1.520 million euro and profit at over 210 million euro.
Krka intends to allocate 134 million euro to investment projects to increase and modernise production capacities and infrastructure this year, it said, adding that the group plans to increase the number of employees in Slovenia and abroad by 3% to over 12,300 at the end of 2020.
Krka's shares closed 2.96% higher at 76.4 euro on the Ljubljana Stock Exchange on Thursday in a turnover of 1.11 million euro, the highest among the blue chips, bourse data showed.
($ = 0.90840 euro)
KRKA d.d. is among the biggest companies in SEE. You can download our SEE Top 100 ranking
here or subscribe to our free Top 100 newsletter
here